Abstract
Basaloid squamous cell carcinoma (BSCC) is a rare, aggressive and distinct variant of squamous cell carcinoma (SCC) of the upper respiratory and digestive tract. We have evaluated disease specific survival (DSS) and overall survival (OS) through Kaplan-Meier method and mortality risk through univariate statistical analysis of Cox in 42 cases of BSCC and other 42 of laryngeal SCC (LSCC) matched for both age and sex. We demonstrated that laryngeal BSCC is a more aggressive tumor than LSCC as is associated to higher nodal recurrence of pathology (5 vs 2 patients, overall risk, OR 2.7), a reduced survival (median survival 34 vs 40 months, OR 3.2 for mortality); in addition, basaloid patients have a higher risk to be affected by second primary tumors (13 vs 3 patients, OR 5.8) and a higher probability to die for this second tumor (Hazard Risk, HR 4.4). The analysis of survival shows an increased mortality risk concurrent with the parameters assessed by univariate analyses that assume a predictive and statistical significance in second tumor and grading in basaloid LSSC.
Highlights
Basaloid squamous cell carcinoma (BSCC) is a high-grade variant of squamous cell carcinoma (SCC) of the upper respiratory and digestive tract [1,2,3,4]
We demonstrated that laryngeal BSCC is a more aggressive tumor than laryngeal SCC (LSCC) as is associated to higher nodal recurrence of pathology (5 vs 2 patients, median survival, overall risk (OR) 2.7), a reduced survival; in addition, basaloid patients have a higher risk to be affected by second primary tumors (13 vs 3 patients, OR 5.8) and a higher probability to die for this second tumor (Hazard Risk, HR 4.4)
Study population was formed by 84 cases of laryngeal carcinoma (74M and 10F) divided into two subgroups: 42 cases of basaloid laryngeal squamous cellular carcinoma (LSCC) (A) and 42 cases of Nonbasaloid LSCC (B)
Summary
Basaloid squamous cell carcinoma (BSCC) is a high-grade variant of squamous cell carcinoma (SCC) of the upper respiratory and digestive tract [1,2,3,4]. It was firstly described in 1986 by Wain et al as a distinct histological variant of SCC and recognized by the World Health Organization (WHO) as a peculiar entity in 1991 [9]. We have analyzed the aggressiveness of laryngeal www.impactjournals.com/oncotarget
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
